 |
HONG KONG, Aug. 19, 2026 /PRNewswire/ — Sino Biopharmaceutical Restricted (HKEX: 01177), a number one innovation-driven pharmaceutical firm in China, introduced the launch of its new international model, SBP Group, throughout its interim outcomes assembly. SBP stands for Science, Breakthroughs and Sufferers: Science is the place the corporate begins; breakthroughs are what it pursues; sufferers are why it does what it does. This philosophy aligns with the Firm’s mission, “Science for a More healthy World.”
The unified identification displays the Firm’s strategic evolution from a number one home biopharmaceutical firm into a worldwide innovator. This transformation is advancing on two fronts: product globalization, by constructing a worldwide pipeline of progressive belongings via in-house R&D and acquisition; and enterprise globalization, via international partnerships and direct industrial growth in key worldwide markets. Supported by continued funding in international expertise, organizational capabilities and infrastructure, the Firm goals to carry progressive medicines to extra sufferers worldwide.
“2026 marks the primary 12 months of executing our globalization technique, and now we have made robust progress,” mentioned Ms. Theresa Tse, Chairwoman of the Board. “SBP Group is dedicated to working with international companions to speed up the worldwide improvement and availability of progressive medicines from China and convey cutting-edge therapies from around the globe to China. Leveraging our AI-driven, totally built-in R&D platform, we intention to advance breakthroughs on the frontiers of science, with the final word purpose of benefiting extra sufferers and enhancing human well being.”
Thus far, the Firm has accomplished 4 out-licensing transactions with MNCs, with mixture upfront funds exceeding US$1 billion and a complete potential deal worth of greater than US$7 billion, alongside over 30 M&A, licensing and strategic partnership transaction. 2026 key transactions embrace (i) the unique licensing to Sanofi of rovadicitinib, a first-in-class twin JAK/ROCK inhibitor, in a transaction valued at as much as US$1.53 billion; and (ii) the unique licensing to AstraZeneca of TQC3721, an inhaled PDE3/4 inhibitor for COPD, in a transaction valued at as much as US$1.9 billion.
About SBP Group
Sino Biopharmaceutical Restricted (HKEX: 01177), referred to herein as “SBP Group”, is a number one innovation-driven pharmaceutical firm in China. The Firm has end-to-end capabilities throughout full worth chain, together with R&D, manufacturing and commercialization. Its product portfolio covers a variety of biologics and small molecule medicine, with a robust management place throughout 4 core therapeutic areas: oncology, liver/cardiometabolic ailments, respiratory/autoimmune ailments, and surgical procedure/analgesia.
